YF476 & Type II Gastric Carcinoids

See also
Status	Clinical Trial	Phase
Completed	`NCT00079833` - Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome	Phase 3
Completed	`NCT00204373` - Treatment of Zollinger-Ellison Syndrome With Prevacid	Phase 4
Completed	`NCT02153398` - A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases	Phase 3

See also

Status

Clinical Trial

Phase

Completed

NCT00079833 - Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

Phase 3

Completed

NCT00204373 - Treatment of Zollinger-Ellison Syndrome With Prevacid

Phase 4

Completed

NCT02153398 - A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT02454075
Study type	Interventional
Source	Trio Medicines Ltd.
Contact
Status	Terminated
Phase	Phase 2
Start date	April 11, 2011
Completion date	June 22, 2012

YF476 and Type II Gastric Carcinoids

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms